Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Breast Neoplasms 47Carcinoma, Hepatocellular 9Triple Negative Breast Neoplasms 7Stomach Neoplasms 6Inflammatory Breast Neoplasms 6Lymphoma, Large B-Cell, Diffuse 4Urinary Bladder Neoplasms 3Non-Muscle Invasive Bladder Neoplasms 3Esophageal Neoplasms 3Recurrence 2Lymphoma 2Breast Neoplasms, Male 2Breast Diseases 2Upper Tract Urothelial Carcinoma 1Thymoma 1Small Cell Lung Cancer Extensive Stage 1Sarcoma 1Prostatic Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Postoperative Complications 1Pancreatic Neoplasms 1Oesophagogastric Cancer 1Neoplastic Cells, Circulating 1Neoplasms, Unknown Primary 1Neoplasms 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell 1Lung Neoplasms 1Liver Neoplasms 1Leiomyosarcoma 1

Interventions

Cyclophosphamide 5fludarabine 4N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 3Gemcitabine 3fludarabine phosphate 2endostar protein 2Melphalan 2Etoposide 2Doxorubicin 2Cisplatin 2Alemtuzumab 2thymoglobulin 1spartalizumab 1selinexor 1pembrolizumab 1Vindesine 1Vincristine 1Sensitivity and Specificity 1Rituximab 1Prednisone 1Prednisolone 1Methylprednisolone 1Interleukin-2 1Flavin-Adenine Dinucleotide 1Epirubicin 1Endostatins 1Drug Therapy 1Dexamethasone 1Cytarabine 1Clinical Protocols 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Lymphoma, T-Cell × Epirubicin × Clear all
NCT02987244 2016-12-08

Chidamide Plus CHOEP Combined With Upfront ASCT in Untreated Peripheral T-cell Lymphoma

Peking Union Medical College Hospital

Phase 1/2 Unknown
100 enrolled
Lymphoid

Lymphoma, T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡